Viral therapy of glioblastoma multiforme.

Of all human malignancies, glioblastoma multiforme (GBM) is among the most refractory to existing therapies despite combination approaches of surgical resection, irradiation, and chemotherapy. The median survival is ∼12–14 mo, regardless of the therapeutic intervention. The 5-y survival of patients with a diagnosis of GBM is less than 9.8% (1). This remarkably poor rate of survival begs the question of why our interventions have not been more beneficial over the last several decades. Cheema et al., in PNAS (2), discuss a unique multifaceted approach to treatment of glioblastoma.